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A B S T R A C T
The coxsackie and adenovirus receptor (CAR) is a transmembrane receptor that plays a key role in controlling
adhesion between adjacent epithelial cells. CAR is highly expressed in epithelial cells and was originally
identiﬁed as a primary receptor for adenovirus cell binding. However, studies over the last 10 years have
demonstrated that CAR plays a key role in co-ordinating cell–cell adhesion under homeostatic conditions
including neuronal and cardiac development and cell junction stability; it has also been implicated in
pathological states such as cancer growth and leukocyte transmigration during inﬂammation. Here we provide
an overview of the functions of CAR as an adhesion molecule and highlight the emerging important role for CAR
in controlling both recruitment of immune cells and in tumorigenesis.
1. Introduction
The Coxsackie and adenovirus receptor CXADR or CAR, also known
as CAR-like membrane protein (CLMP) was ﬁrst identiﬁed as a high-
aﬃnity receptor for the coxsackie B virus and adenovirus (Ad)
serotypes 2 and 5 (Bergelson et al., 1997) and was subsequently shown
to belong to the Junction Adhesion Molecule (JAM) family within the
immunoglobulin (Ig) superfamily (IgSF) of proteins that localise in tight
junctions and along the lateral membrane of epithelial cells (Coyne and
Bergelson, 2005). JAM proteins are also found in intercellular junctions
of endothelial cells and on the surface of leukocytes, platelets and
eyrthrocytes (Luissint et al., 2014). JAM proteins have been implicated
in a diverse array of functions involving cell–cell adhesion including
barrier function, leukocyte migration, platelet activation angiogenesis
and reovirus binding (Garrido-Urbani et al., 2014). JAMs are type I
transmembrane glycoproteins, composed of two extracellular Ig-like
domains, one transmembrane domain and one cytoplasmic tail of
variable length containing a PDZ domain. The Ig domains allow for
both homo and heterodimerisation in trans. The JAM family include a
distinct group sometimes referred to as the “classical” JAM proteins
that comprises: JAM-A, JAM-B and JAM-C. CAR, Endothelial Selective
Adhesion Molecule (ESAM), JAM-L and JAM-4 make up a separate
subfamily and have longer cytoplasmic tails. JAMs associate with
adaptor/signalling proteins through the PDZ domain in the C-terminus
and homo or hetero-dimerize with other JAMs via the extracellular
domain (Garrido-Urbani et al., 2014).
2. Structure of CAR
The murine and human CAR genes are composed of 8 exons and are
located on the chromosome 16 and chromosome 21 (21q21.1),
respectively, from which diﬀerent isoforms are generated by alternative
splicing (Matthaus et al., 2016). Its predominant isoform, found at the
cell membrane is a 346 amino acid, 46 kDa transmembrane protein.
The structure of CAR comprises an extracellular domain, a transmem-
brane region and an approximately 15 kDa cytoplasmic tail (Fig. 1A);
(Cohen et al., 2001). As with other members of the JAM family, the
extracellular domain is made up of two Ig components: the N-terminal
located domain belongs to the V-subtype of Ig domains (refereed as D1)
and is connected to the membrane proximal Ig domain of the C2-type Ig
domain, referred to as D2. Both domains are connected by a short
linker, which is proposed to potentially provide ﬂexibility in the
extracellular part of the protein, and contain glycosylation and
palmitoylation sites which are thought to regulate the function of
CAR (Excoﬀon et al., 2007). Cysteines 259 and 260 within the
cytoplasmic domain of CAR are palmitoylation sites and are responsible
for CAR localisation at the plasma membrane (van't Hof and Crystal,
2002). Studies using truncation mutants of CAR have shown that amino
acids 261–315, which contain the tyrosine/threonine/serine phosphor-
ylation sites, are required to both enable calyculin-driven phosphoryla-
tion of CAR and activate p44/42 in response to homo-dimerisation in
trans (Farmer et al., 2009; Morton et al., 2013). Furthermore, two
serine/threonine (290/293) phosphorylation sites have been shown to
inﬂuence CAR mediated endocytosis of E-cadherin (Morton et al.,
2013). In addition to this, the cytoplasmic tail contains one postulated
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tyrosine phosphorylation site although to date this remains unexplored
in the function of CAR (Fig. 1A).
CAR is able to homodimerise through its IgG like domains. In
crystals, the extracellular region of CAR forms U-shaped homodimers
through the binding of their D1 domains (Matthaus et al., 2016).
Although initial studies suggested that the membrane-proximal D2 Ig
domain might not be necessary for correct adenovirus binding or
homodimer formation, further biochemical binding and adhesion
studies suggest that the interaction between D1 and D2 domains are
implicated in homophilic interactions. It is thought that trans-homo-
philic interaction may be initiated by CAR monomers from opposing
cells via through the D1-D1 interface. CAR mediated adhesion could
then be further strengthened by a change in the conformation which
relocates the Ig domains in a manner in which they bind by forming D1-
D2 interfaces in a linear arrangement (Matthaus et al., 2016; Patzke
et al., 2010).
Aside from these homophilic interactions, CAR is able to hetero-
dimerise with both extracellular and intracellular molecules. CAR
binding with extracellular matrix proteins such as ﬁbronectin, agrin
or tenascin-R has been observed to occur via the CAR D2 domains
(Matthaus et al., 2016). CAR can also interact with JAM-C and JAM-L
(Garrido-Urbani et al., 2014). CAR and JAM-L interaction is thought to
have an immune regulatory role in the activation of T-cells (Verdino
and Wilson, 2011). γd T-cells express JAM-L on their surface and upon
binding of CAR, signalling pathways are activated, including the
phosphoinositide-3-kinase (PI-3-K) pathway, leading to cell prolifera-
tion and cytokine production (Verdino et al., 2010). The C-terminal
PDZ intracellular binding domain is also important in CAR function at
the cell membrane, as it enables it to bind to multiple other structural
proteins, including ZO-1 (Zona occludens-1), membrane-associated
guanylate kinase 1b (MAGI-1b), protein interacting with protein C
kinase (PICK1), postsynaptic density 95 (PSD-95), Ligand of-Numb
protein-X (LNX) and LNX2 (Garrido-Urbani et al., 2014). All these
interactions between CAR and intracellular proteins suggests that CAR
is present in the plasma membrane in multiple protein complexes and
highlights its importance in regulating epithelial homeostasis. In
support of this, phosphorylation of CAR in human epithelial cells play
a key role in determining epithelial cell adhesion through control of E-
cadherin stability at cell–cell junctions (Hussain et al., 2011; Morton
et al., 2013).
3. Expression and activation
CAR is expressed and regulated in many organs including brain,
heart, lung, liver, testis, pancreas or kidney (Matthaus et al., 2016).
CAR expression levels change during embryonic development and the
importance of this has been highlighted by the fact that deletion of CAR
in the mouse leads to an embryonic lethal phenotype at days 11.5–13.5
due of malformation of the heart and haemorrhage (Dorner et al.,
2005). CAR deﬁcient embryos demonstrate impaired lymphatic en-
dothelial cell adhesion, which impairs the separation of blood and
lymphatic vessels (Mirza et al., 2012). CAR is also strongly expressed
the neural tube and from E10.5, throughout the brain (Patzke et al.,
2010). CAR conditional knockout adult mice have dilated intestinal
tract, atrophy of the exocrine pancreas, complete atrio-ventricular
block and abnormal thymopoiesis (Pazirandeh et al., 2011). These
mice also show disrupted intercellular contacts in the myocardium with
altered localization of connexin 45, β-catenin and ZO-1 preceding
cardiac dysfunction (Lim et al., 2008). CAR expression is also abundant
in axon tracks throughout the adult brain, at the presynapse in some
Fig. 1. CAR function and localisation.
(A) Schematic representation of CAR and associated binding partners (B) Confocal images of Human Bronchial Epithelial Cells (HBEC) overexpressing CAR-GFP and stained with E-
cadherin (upper panel) and ZO-1 (bottom panel).
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mature neurons, and recruited to activated presynapses. Genetic
deletion of CAR in the mouse brain aﬀects adult neurogenesis, synaptic
function, and behaviour (Zussy et al., 2016). These ﬁndings underline
the importance of CAR in regulating multiple diﬀerent types of cell–cell
interactions and suggest a key regulatory role of this receptor in
mediating dynamic cell adhesion processes during development and
homeostasis.
CAR has a role in the dynamic control and regulation of epithelial
cell junction formation and stability through homodimerisation in trans
with the extracellular D1 domains of other CAR proteins in adjacent
cells. CAR overexpression in CHO cells has been shown to limit the
passage of ions and macromolecules across the epithelium and treat-
ment of cells with soluble CAR ectodomain disrupts tight junction
formation due to competitive binding across two adjacent membranes,
suggesting strengthening of tight junctions by CAR homodimerisation in
trans (Cohen et al., 2001). However, this role for CAR appears to
potentially be organ speciﬁc as increased permeability in the heart but
not in the gut of mice (Pazirandeh et al., 2011). CAR has been shown to
interact directly with scaﬀolding proteins present in tight junctions,
speciﬁcally ZO-1 and Multi-PDZ Domain Protein-1 (MUPP1) (Cohen
et al., 2001). Both of these scaﬀolding proteins bind to F-actin,
therefore the interaction of CAR with these two proteins implicates
CAR in the potential co-ordination of cytoskeletal dynamics. Indeed,
CAR has been shown to interact and contribute to F-actin bundling in
neurons and has additionally been suggested to associate with the F-
actin regulatory molecule Rho Kinase (ROCK) (Saito et al., 2014). CAR
has also been shown to regulate migration in U87 glioma cells via the
binding of tubulin to the cytoplasmic tail of CAR (Fok et al., 2007).
In addition to roles within the tight junction, basolateral localisation
of CAR at cell–cell adhesion sites has been demonstrated in both airway
epithelial cells and cardiomyocytes, and co-localisation of CAR and N-
Cadherin has also been observed in Sertoli cells (Wang et al., 2007).
Cardiac myocytes overexpressing CAR also show severely disrupted
adherens junctions in vivo, resulting in cardiomyopathy (Caruso et al.,
2010). Moreover, CAR overexpression destabilises junctional E-Cadher-
in in bronchial epithelial cells by promoting endocytosis of E-Cadherin
(Morton et al., 2013). The presence of Ad also aﬀects E-Cadherin
dynamics; this is mediated by CAR clustering and subsequent binding of
β-catenin to disrupt E-Cadherin localisation (Hussain et al., 2011).
These ﬁndings combined demonstrate that CAR can act at a number of
diﬀerent points to regulate cell–cell adhesion integrity and this occurs
through direct or indirect eﬀects on the actin cytoskeleton. The precise
mechanisms by which CAR co-ordinates these events remain to be fully
explored (see Fig. 1B).
4. Biological functions in inﬂammation
In addition to controlling cell–cell adhesion integrity in home-
ostasis, CAR is emerging as an important player in the control of
inﬂammation. CAR expression is upregulated in rat cardiomyocytes in
chronic autoimmune inﬂammatory conditions (Ito et al., 2000).
However, CAR expression on normal human bronchial epithelial cells
or A549 lung epithelial cells is unaﬀected by cytokine treatments
(Vincent et al., 2004). Recent work has also shown that epithelial cells
from patients with cystic ﬁbrosis express CAR at higher levels compared
with healthy donor cells, which leads to increased infectivity with Ad
(Sharma et al., 2017). We have also recently shown that CAR is hyper-
phosphorylated in vivo in both acute and chronic lung inﬂammation
models but that CAR expression levels remain unchanged (Morton
et al., 2016). Conversely, CAR expression is decreased in primary
Fig. 2. Functions of CAR in disease.
(A) Diagrammatic representation of the role of CAR in trans-epithelial migration. Leukocytes adhere to the basolateral side of the epithelium before trans-epithelial migration along the
basolateral membrane. Adhesion molecules such as JAMs and CAR promote this migration (adapted from Garrido-Urbani et al., 2014). (B) Confocal image of THP-1 cells undergoing
trans-epithelial migration. THP-1 human monocytes cells were added to conﬂuent monolayers of HBEC and ﬁxed after 24 h. THP-1 cells are shown in blue, HBEC cells expressing CAR-
GFP are shown in green and actin in red. Note clustered CAR around the THP1 cell. (C) CAR expression determined by immunohistochemistry in formalin-ﬁxed paraﬃn-embedded section
a human lung adenocarcinoma tissue. Panel on right shows zoom of denoted area.
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cultures of murine hippocampal neurons and adult murine neural
progenitor cells when incubated with TNFα and IFN-γ in a dose-
dependent manner. Similarly, a pro-inﬂammatory environment induced
by Alzheimer disease and/or systemic inﬂammation is associated with
CAR loss in the hippocampus (Zussy et al., 2016). These apparently
conﬂicting ﬁndings suggest that tissue-speciﬁc regulation of CAR
transcription and post-translational modiﬁcation may be dependent
upon the local immune cell populations that have yet to be precisely
characterised.
CAR interactions with other members of the JAM family are a
potential mechanism by which CAR may contribute to control of local
immune responses. CAR expressed on skin epithelial cell membranes
binds to JAM-L on γδ T cells (Verdino et al., 2010). This interaction also
occurs between CAR on gut epithelial cells and JAM-L on neutrophils
(Zen et al., 2005). Similarly, have demonstrated that in trans homo-
dimers of CAR within epithelial cell–cell adhesions are phosphorylated
in response to exogenous TNFα and that this contributes to eﬃcient
transmigration of monocytes and neutrophils, both in vitro and in vivo,
suggesting that CAR may be an important receptor in the control of
inﬂammation (Morton et al., 2016). As neutrophils and T cells play a
role in host immunity, these data suggest that CAR may be ideally
positioned to modulate the immune response from the epithelial or
endothelial cell compartments. Further work is needed to deﬁne the
mechanisms by which CAR-dependent co-ordination of immune cell
adhesion and transmigration occurs, as well as potential roles for CAR
in diﬀerent pathological immune responses in vivo (see Fig. 2A and B).
5. Potential medical relevance
In addition playing a role in inﬂammation and autoimmune
diseases, CAR has also been described to contribute to cancer progres-
sion (Fig. 2C). The role of CAR in tumorigenesis has been largely been
suggested to cell–cell adhesion. In that sense, CAR expression is
downregulated in parotid glands, colon cancer, prostate cancers and
bladder cancer cells whilst increased CAR expression has been reported
in cervical, ovarian and glioblastoma cancer cell lines (Reeh et al.,
2013). Using a multi-tumour array analysis, Reeh et al. showed a
signiﬁcant increased CAR levels at the tissue level in comparison to
healthy patients in basalioma, larynx carcinoma, Warthin’s tumour,
lung, cervical, endometrial, ovarian and bladder cancer, thyroid
adenoma, carcinoma and neuroblastoma. Conversely, a decrease in
CAR expression was seen in pleomorphic adenoma of the parotid gland,
colon and prostate cancer, as well as subtypes of renal cell cancers
(Reeh et al., 2013). Diﬀerences in CAR expression were observed at
diﬀerent stages of malignancy, indicating the protein expression is
either increased or lost as the disease progresses (Reeh et al., 2013). The
variability in CAR expression among diﬀerent cancer types may be due
to pre-existing endogenous levels of CAR expression within these
diﬀerent tissues.
CAR has also been shown to have both tumour suppressor and
promoting functions, depending on the type of cancer. For example, in
both bladder cancer the overexpression of CAR decreases cell growth in
vitro and in gastric cancer cells the depletion of CAR increases
migration, proliferation and invasion (Anders et al., 2009). By contrast,
reduction of CAR resulted in reduced cell growth in oral squamous
carcinoma and in colony formation, adhesion, transwell migration and
xenograft tumorigenesis in lung cancer cell lines (Saito et al., 2014).
CAR expression correlates with the expression of mesenchymal mar-
kers, suggesting a potential role in Epithelial to Mesenchymal transition
(EMT) (Zhang et al., 2012). Finally, CAR expression has been associated
with cancer stem cell phenotype. CAR overexpressing cells are more
resistant to paclitaxel and radiation, self-renewing, and more tumori-
genic than parental cells and the siRNA depletion of CAR inhibits these
functions (Zhang et al., 2012). This highlights the potential of CAR in
tumour progression, although the mechanism of how CAR mediates
these phenotypes remains poorly deﬁned.
CAR is now a well-recognised key mediator of cell–cell adhesion in a
range of diﬀerent tissues and even though a number of the precise
mechanistic pathways remain poorly understood, it is clear that CAR
can regulate junction dynamics through association with adaptor
proteins, cytoskeletal remodelling and additional indirect signalling
pathways. Expression of CAR in cancer cells contributes to tumour
growth and as CAR has been shown to be an important receptor in the
control of inﬂammation, this raises the possibility that CAR may also
act on immune cell inﬁltration into tumours. Although the mechanisms
by which CAR operates within these diﬀerent disease settings remains
unclear, given the restricted expression of CAR in adult tissues and the
altered regulation in disease, we propose that CAR represents a
potentially important therapeutic target in inﬂammatory disease and
in cancer.
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